• The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of glucosamine (M01AX05)

    | 03 March 2011 |

    Clinical studies have called into question the efficacy of glucosamine for the alleviation of painful osteoarthritis. This has contributed to the Danish Medicines Agency’s decision to initiate ad hoc reassessment of glucosamine-containing medicines, which today have general conditional reimbursement when prescribed for the alleviation of symptoms of mild to moderate osteoarthritis and when prescribed to old-age pensioners.